Ingevity (NYSE: NGVT) reported Q4 EPS of $0.57, $0.30 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $383.6 million versus the consensus estimate of $392.9 million.

GUIDANCE:

The company announces full year 2023 guidance for sales between $1.9 billion and $2.1 billion and adjusted EBITDA between $495 million and $515 million.

For earnings history and earnings-related data on Ingevity (NGVT) click here.